Patheon's move to Puerto Rico is shaping up to be the worst
decision the contract manufacturer has ever made, resulting in
massive losses in the third quarter of 2006 and leading management
to entertain the possibility of a sell-out.
Bentley Pharmaceuticals has announced it will use the North
Carolina facilities of US-based services provider Cardinal Health
for the scale-up and manufacture of the clinical supplies of its
new intranasal insulin product.
Wyeth has entered into a global agreement that allows it to use
Intracell's synthetic adjuvant IC31 in the formulation of five of
its investigational vaccines, aiming to simply mix it with antigens
without the need for conjugation.
Offshoring contract manufacturing is not the only option for large
pharma firms looking to drive productivity and efficiency gains in
drug manufacturing, warns a new report from independent market
After selling a manufacturing plant in Texas to Cardinal Health two
years ago, Adams Respiratory Therapeutics has reacquired the
facility in order to produce its expectorant Mucinex (guaifenesin
extended-release), responding to a...
Canadian contract manufacturer Patheon has teamed up with specialty
pharmaceutical firm Depomed to offer its clients a controlled
release formulation which can grant their drugs increased
bioavailability and less frequent dosing.
Despite its consolidation, the competitive consumable sector still
offers potential for rapid growth and better profits in the
biopharmaceutical industry, while contract bioprocessing services
will be increasingly in demand, according...
For the first time Merck has opened the doors of its
under-construction manufacturing plant in North Carolina to public
officials, boasting it will eventually contribute about two-thirds
of its annual live-virus vaccine production.
Newly-approved pearlescent pigments that can produce sparkly
metallic, satiny and shimmery finishes on drug coatings could be
used as one additional step in the fight against counterfeiting,
say its developers, EMD Chemicals - part...
India's potential to further boost its already dominant role in
global generics production, as well as an offshore location of
choice for contract manufacturing, presents an opportunity worth an
estimated $48bn (€38bn) in 2007,...
More problems at Patheon's Puerto Rican production facilities in
the third quarter of 2006 are expected to reduce the contract
manufacturer's earnings before interest, tax, depreciation and
amortisation (EBITDA) by more...